Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

SEPN

Septerna Inc

Nov 14 • 04:00PM ET

23.26

+4.02 20.92 %

Healthcare • Biotechnology • USA • NASD

Held by: VTI IWM VXF IWN DWAS SCHA VTWO AVSC SCHB VTWV

Index	RUT	P/E	-	EPS (ttm)	-1.51	Insider Own	39.99%	Shs Outstand	44.64M	Perf Week	25.69%
Market Cap	1.04B	Forward P/E	-	EPS next Y	-1.27	Insider Trans	-0.02%	Shs Float	26.94M	Perf Month	3.10%
Enterprise Value	591.44M	PEG	-	EPS next Q	-0.29	Inst Own	63.35%	Short Float	7.52%	Perf Quarter	100.73%
Income	-58.81M	P/S	47.24	EPS this Y	83.16%	Inst Trans	-1.83%	Short Ratio	7.15	Perf Half Y	136.43%
Sales	22.05M	P/B	2.67	EPS next Y	-3.89%	ROA	-15.06%	Short Interest	2.03M	Perf YTD	1.59%
Book/sh	8.71	P/C	2.20	EPS next 5Y	32.73%	ROE	-22.38%	52W High	28.99 -19.75%	Perf Year	-1.34%
Cash/sh	10.59	P/FCF	10.10	EPS past 3/5Y	-56.62% -	ROIC	-14.32%	52W Low	4.17 457.91%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	92.81%	Volatility	10.16% 6.60%	Perf 5Y	-
Dividend TTM	-	EV/Sales	26.82	EPS Y/Y TTM	-269.99%	Oper. Margin	-405.95%	ATR (14)	1.47	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	6.53	Sales Y/Y TTM	2147.20%	Profit Margin	-266.77%	RSI (14)	66.71	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	6.53	EPS Q/Q	138.77%	SMA20	12.61%	Beta	4.16	Target Price	27.67
Payout	-	Debt/Eq	0.06	Sales Q/Q	12113.07%	SMA50	20.26%	Rel Volume	5.37	Prev Close	19.24
Employees	75	LT Debt/Eq	0.06	Earnings	Nov 10 BMO	SMA200	95.28%	Avg Volume	283.16K	Price	23.26
IPO	Oct 25, 2024	Option/Short	Yes / Yes	EPS/Sales Surpr.	45.99% -76.55%	Trades		Volume	1,521,621	Change	20.92%

Date	Action	Analyst	Rating Change	Price Target Change
Today	Upgrade	Wells Fargo	Equal Weight → Overweight
Jun-23-25	Initiated	H.C. Wainwright	Buy	$26
Feb-18-25	Downgrade	Wells Fargo	Overweight → Equal Weight	$14
Nov-19-24	Initiated	Wells Fargo	Overweight	$43
Nov-19-24	Initiated	TD Cowen	Buy
Nov-19-24	Initiated	JP Morgan	Overweight	$38
Nov-19-24	Initiated	Cantor Fitzgerald	Overweight	$50

Nov-10-25 08:20AM	Septerna, Inc. (SEPN) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Septerna Highlights Company Progress and Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Nov-06-25 09:15AM	Iovance Biotherapeutics (IOVA) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
Nov-03-25 08:00AM	Septerna to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-31-25 04:56AM	Strength Seen in Moderna (MRNA): Can Its 13.9% Jump Turn into More Strength? (Zacks)
05:57AM	Loading…
Oct-22-25 05:57AM	Arcturus Therapeutics (ARCT) Moves 7.7% Higher: Will This Strength Last? (Zacks)
Oct-15-25 04:15PM	Novo Nordisk's Akero Therapeutics Buy Targets Eli Lilly's Lead (MarketBeat)
Oct-09-25 10:13AM	Strength Seen in Septerna, Inc. (SEPN): Can Its 7.0% Jump Turn into More Strength? (Zacks)
Oct-03-25 08:42AM	Are Options Traders Betting on a Big Move in Septerna Stock? (Zacks)
Sep-29-25 04:01PM	Septerna Appoints Veteran Biotechnology Leader Keith Gottesdiener, M.D., to its Board of Directors (GlobeNewswire)
Aug-27-25 08:00AM	Septerna to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-21-25 08:00AM	Septerna Announces Dosing of the First Participants in Phase 1 Clinical Trial of SEP-631, an Oral Small Molecule MRGPRX2 Negative Allosteric Modulator for the Treatment of Mast Cell-Driven Diseases (GlobeNewswire) +5.50%
Aug-14-25 08:15AM	Lilly signs $1.3 billion deal with Superluminal to discover obesity medicines using AI (Reuters)
Aug-11-25 04:01PM	Septerna Highlights Business Progress and Reports Second Quarter 2025 Financial Results (GlobeNewswire)
May-29-25 08:00AM	Septerna to Present at Jefferies Global Healthcare Conference (GlobeNewswire)
07:45AM	Loading…
May-23-25 07:45AM	Analysts Think These Stocks Could More Than Double in Value (MarketBeat)
May-21-25 09:55AM	Does Septerna, Inc. (SEPN) Have the Potential to Rally 151.27% as Wall Street Analysts Expect? (Zacks)
May-15-25 04:01PM	Septerna Highlights Business Progress and Reports First Quarter 2025 Financial Results (GlobeNewswire)
10:00AM	ETFs to Capitalize on the Novo Nordisk-Septerna Deal (Zacks)
08:46AM	Septerna Stock Surges on Oral Obesity Drug Deal With Novo Nordisk (Zacks)
07:45AM	Is It Time to Buy the Dip in Novo Nordisk Stock? (MarketBeat)
01:45AM	Novo Nordisk and Septerna Strike $2.2 Billion Deal to Develop Obesity Pills (The Wall Street Journal)
May-14-25 04:06PM	Novo Nordisk Inks A Major Obesity Deal, Sending Shares Of New Partner Septerna Skyrocketing (Investor's Business Daily) +50.97%
02:22PM	eToro's Nasdaq debut, Exelixis outlook, SepternaNovo deal (Yahoo Finance Video)
01:29PM	Novo Nordisk taps Septerna in $2.2bn deal for oral obesity therapies (Pharmaceutical Technology)
10:28AM	Novo Nordisk Rises on Weight-Loss News. Its a Huge Deal for This Stock. (Barrons.com)
09:35AM	Novo Nordisk, Septerna sign $2.2B deal to develop weight-loss pill (Yahoo Finance Video)
09:32AM	Novo Nordisk's latest bet on obesity pills: $2.2 billion for biotech Septerna (Yahoo Finance)
09:32AM	Novo Nordisk's latest bet on obesity pills: $2.2 billion for biotech Sapterna (Yahoo Finance)
07:03AM	Novo Nordisk strikes $2.2 billion deal with Septerna to develop new obesity treatments (Reuters)
09:55AM	Loading…
Apr-16-25 09:55AM	Wall Street Analysts Predict a 207.31% Upside in Septerna, Inc. (SEPN): Here's What You Should Know (Zacks)
Mar-31-25 02:34PM	Biotech Stocks Q1 2025 Recap: Winners And Underperformers (Seeking Alpha) -5.08%
Mar-27-25 08:00AM	Septerna Provides Corporate Overview and Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Mar-14-25 11:26AM	Septerna, Inc. (SEPN): Among Top Insider Purchases Last Month (Insider Monkey)
Mar-05-25 06:59PM	Septerna, Inc. (SEPN): Among The Stocks With At Least $30 Million In Insider Spending Recently (Insider Monkey) +7.25%
Feb-26-25 08:00AM	Septerna to Present at TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
Feb-18-25 08:00AM	Septerna Announces Discontinuation of SEP-786 Phase 1 Clinical Trial and Plans to Advance Next-Generation Oral Small Molecule PTH1R Agonist (GlobeNewswire) -46.99%
Feb-14-25 06:45AM	Its not for the faint of heart. How 3 CEOs took their biotechs public (BioPharma Dive) +12.21%
Feb-06-25 07:48AM	Septerna, Inc. (SEPN): Among the Best Rebound Stocks to Invest In Now (Insider Monkey)
Jan-06-25 07:00AM	Septerna Expands Leadership with Appointment of Industry Veteran Gil Labrucherie as Chief Financial Officer (GlobeNewswire) -6.75%
Dec-18-24 08:00AM	Septerna to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-21-24 11:12PM	Septerna, Inc. Reports Q3 2024 Financials and Progress (TipRanks)
Nov-20-24 07:00AM	Septerna Reports Third Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire) -7.02%
05:10AM	Septerna initiated with an Overweight at JPMorgan (TipRanks)
Oct-30-24 04:41PM	Septerna Announces Closing of $331.2 Million Upsized Initial Public Offering (GlobeNewswire) +12.32%
Oct-24-24 09:47PM	Septerna Prices Upsized Initial Public Offering (GlobeNewswire)

Septerna, Inc. is a clinical-stage biotechnology company, which engages in pioneering a new era of G protein-coupled receptor oral small molecule drug discovery powered by proprietary Native Complex PlatformTM. Its pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. The company was founded by Robert Joseph Lefkowitz, Arthur Christopoulos, Patrick Sexton, and Jeffrey T. Finer in December 2019 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Long Daniel D.	SVP, Drug Discovery	Nov 10 '25	Sale	18.06	3,501	63,223	92,911	Nov 13 08:13 PM
DANIEL DAVID LONG	Officer	Nov 10 '25	Proposed Sale	18.06	3,501	63,223		Nov 10 04:07 PM
Klein Uwe	SVP, Biological Sciences	Aug 18 '25	Option Exercise	4.10	23,008	94,367	23,008	Aug 19 05:02 PM
Finer Jeffrey	CEO and President	Apr 02 '25	Option Exercise	2.76	50,000	138,000	821,907	Apr 04 04:13 PM
Finer Jeffrey	CEO and President	Apr 03 '25	Option Exercise	2.76	5,000	13,800	826,907	Apr 04 04:13 PM
Ezekowitz Alan	Director	Mar 07 '25	Buy	6.93	13,319	92,270	117,420	Mar 10 04:18 PM
Ezekowitz Alan	Director	Mar 06 '25	Buy	6.00	41,355	248,130	104,101	Mar 06 09:02 PM
Ezekowitz Alan	Director	Mar 05 '25	Buy	5.82	37,835	220,260	62,746	Mar 06 09:02 PM
Ezekowitz Alan	Director	Mar 04 '25	Buy	6.35	7,491	47,544	24,911	Mar 06 09:02 PM
Finer Jeffrey	CEO and President	Feb 25 '25	Buy	5.68	10,000	56,765	764,907	Feb 27 06:53 PM
Finer Jeffrey	CEO and President	Feb 26 '25	Buy	5.70	4,000	22,796	768,907	Feb 27 06:53 PM
Finer Jeffrey	CEO and President	Feb 27 '25	Buy	5.80	3,000	17,400	771,907	Feb 27 06:53 PM
Labrucherie Gil M	Chief Financial Officer	Feb 25 '25	Buy	5.59	6,282	35,116	36,282	Feb 27 06:51 PM
Labrucherie Gil M	Chief Financial Officer	Feb 27 '25	Buy	5.85	3,718	21,750	40,000	Feb 27 06:51 PM
Third Rock Ventures VI, L.P.	10% Owner	Feb 24 '25	Buy	6.00	18,861	113,147	4,211,659	Feb 26 04:15 PM
Third Rock Ventures VI, L.P.	10% Owner	Feb 20 '25	Buy	5.92	612,674	3,627,030	3,765,130	Feb 24 04:15 PM
Third Rock Ventures VI, L.P.	10% Owner	Feb 21 '25	Buy	5.94	427,668	2,540,348	4,192,798	Feb 24 04:15 PM
Labrucherie Gil M	Chief Financial Officer	Feb 20 '25	Buy	5.88	14,500	85,234	25,000	Feb 21 06:06 PM
Labrucherie Gil M	Chief Financial Officer	Feb 19 '25	Buy	5.51	10,500	57,813	10,500	Feb 21 06:06 PM
Labrucherie Gil M	Chief Financial Officer	Feb 21 '25	Buy	5.85	5,000	29,250	30,000	Feb 21 06:06 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SEPN

Septerna Inc

Upgrade your FINVIZ experience